Rapid Response of Advanced Squamous Non-Small Cell Lung Cancer with Thrombocytopenia after First-Line Treatment with Pembrolizumab Plus Autologous Cytokine-Induced Killer Cells

Zhenzhen Hui; Xinwei Zhang; Baozhu Ren; Runmei Li; Xiubao Ren

doi:10.3389/fimmu.2015.00633

Rapid Response of Advanced Squamous Non-Small Cell Lung Cancer with Thrombocytopenia after First-Line Treatment with Pembrolizumab Plus Autologous Cytokine-Induced Killer Cells

Front Immunol. 2015 Dec 17:6:633. doi: 10.3389/fimmu.2015.00633. eCollection 2015.

Authors

Zhenzhen Hui¹, Xinwei Zhang¹, Baozhu Ren¹, Runmei Li¹, Xiubao Ren²

Affiliations

¹ Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; National Clinical Research Center for Cancer, Tianjin, China; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China; Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.
² Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China; National Clinical Research Center for Cancer, Tianjin, China; Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, China; Key Laboratory of Cancer Prevention and Therapy, Tianjin, China; Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.

Abstract

We present the first clinical evidence of advanced squamous non-small cell lung cancer with severe thrombocytopenia showing dramatic improvement after first-line treatment with pembrolizumab plus autologous cytokine-induced killer cells.

Keywords: cytokine-induced killer cells; immunotherapy; non-small cell lung cancer; pembrolizumab; thrombocytopenia.